Business Description

AbbVie Inc. is a global, research-based biopharmaceutical company that discovers, develops, and commercializes advanced therapies. Spun off from Abbott Laboratories in 2013, the company focuses on key therapeutic areas including immunology, oncology, neuroscience, and aesthetics. It is known for its biologic drugs such as Humira, Skyrizi, and Rinvoq, as well as its Botox franchise.

Everything on AbbVie Inc.

Revenue (FY2025) $61.16B
YoY growth +8.6%
Operating margin 24.6%
Direction Expanding
Gross margin 70.2%
Net margin 6.9%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗
Robert A. Michael — Chairman of the Board and Chief Executive Officer View full profile ↗ Roxanne S. Austin — Lead Independent Director; President, Austin Investment Advisors View full profile ↗ William H.L. Burnside — Retired Senior Vice President and Director, The Boston Consulting Group View full profile ↗ Jennifer L. Davis — Chief Executive Officer, Health Care, Procter & Gamble View full profile ↗ Thomas J. Falk — Retired Chairman and Chief Executive Officer, Kimberly-Clark Corporation View full profile ↗ Thomas C. Freyman — Retired Executive Vice President, Finance and Administration, Abbott Laboratories View full profile ↗ Brett J. Hart — President, United Airlines Holdings, Inc. View full profile ↗ Melody B. Meyer — Retired President, Chevron Asia Pacific Exploration and Production View full profile ↗ Susan E. Quaggin, M.D. — Chair of Medicine, Northwestern University Feinberg School of Medicine View full profile ↗ Edward J. Rapp — Retired Group President, Caterpillar Inc. View full profile ↗ Rebecca B. Roberts — Retired President, Chevron Pipe Line Company View full profile ↗ Frederick H. Waddell — Retired Chairman and Chief Executive Officer, Northern Trust Corporation View full profile ↗ Robert J. Alpern, M.D. — Ensign Professor of Medicine and Physiology and Former Dean of Yale School of Medicine View full profile ↗ Scott T. Reents — Executive Vice President, Chief Financial Officer View full profile ↗ Demetris D. Crum — Executive Vice President, Chief Human Resources Officer View full profile ↗ Nicholas J. Donoghoe, M.D. — Executive Vice President, Chief Business and Strategy Officer View full profile ↗ Azita Saleki-Gerhardt, Ph.D. — Executive Vice President, Chief Operations Officer View full profile ↗ Perry C. Siatis — Executive Vice President, General Counsel and Secretary View full profile ↗ Jeffrey R. Stewart — Executive Vice President, Chief Commercial Officer View full profile ↗ Roopal Thakkar, M.D. — Executive Vice President, Research & Development and Chief Scientific Officer View full profile ↗ David R. Purdue — Senior Vice President, Controller View full profile ↗
AbbVie acquires Allergan plc — Medical aesthetics, neuroscience, eye care & immunology · 2020 View full deal ↗ AbbVie acquires Pharmacyclics, Inc. — Hematologic oncology · 2015 View full deal ↗ AbbVie acquires ImmunoGen, Inc. — Oncology (solid tumors / ADCs) · 2024 View full deal ↗ AbbVie acquires Cerevel Therapeutics Holdings, Inc. — Neuroscience · 2024 View full deal ↗ AbbVie acquires Stemcentrx, Inc. — Oncology (solid tumors) · 2016 View full deal ↗ AbbVie acquires Capstan Therapeutics, Inc. — In vivo cell engineering / immunology · 2025 View full deal ↗ AbbVie acquires Aliada Therapeutics Holdings, Inc. — Neuroscience (CNS) · 2024 View full deal ↗ AbbVie acquires Gilgamesh Pharmaceuticals, Inc. — Neuroscience (psychiatry) · 2025 View full deal ↗ AbbVie acquires Nimble Therapeutics, Inc. — Immunology · 2025 View full deal ↗ AbbVie acquires Celsius Therapeutics, Inc. — Immunology (IBD) · 2024 View full deal ↗ AbbVie acquires Syndesi Therapeutics SA — Neuroscience · 2022 View full deal ↗ AbbVie acquires Landos Biopharma, Inc. — Immunology (IBD) · 2024 View full deal ↗

Share Repurchase Program

Total authorized
December 2018 stock repurchase authorization, increased by $5.0 billion on February 16, 2023
Remaining (FY2025)
$2.9 billion as of December 31, 2025
Latest FY repurchased
$606 million (3 million shares repurchased in 2025; 7 million shares for $1.3 billion in 2024)

Named Competitors

IL-23 inhibitorsIL-17 inhibitorsJAK inhibitorsBiosimilarsBTK inhibitorsAntibody-drug conjugates (ADCs)Cell therapiesBotox competitor products

Customer Concentration

In 2025, three wholesale distributors -- McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc. -- accounted for substantially all of AbbVie's pharmaceutical product sales in the United States. No individual wholesaler accounted for greater than 43% of AbbVie's 2025 gross revenues in the U.S. AbbVie states it has no single customer that, if lost, would have a material adverse effect on its business.

Recent SEC Filings

2026-07-06 Reported quarterly results View filing ↗
2026-06-22 Regulation FD disclosure View filing ↗
2026-05-12 Shareholder vote results View filing ↗
2026-04-29 Reported quarterly results View filing ↗
2026-04-03 Reported quarterly results View filing ↗
2026-03-04 Other event View filing ↗
2026-02-26 Other event View filing ↗
2026-02-04 Reported quarterly results View filing ↗
2026-01-07 Reported quarterly results View filing ↗
2025-10-31 Reported quarterly results View filing ↗
2025-10-03 Reported quarterly results View filing ↗
2025-09-11 Regulation FD disclosure View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.